Comparative study of the specific activity of soft application drugs with vinpocetine
Keywords:violation of cerebral blood flow, circulation, vinpocetine, soft application drugs, neuroprotective effect
In modern neurology, the main component of successful treatment of cerebrovascular pathology is pharmacotherapy. At the same time, the arsenal of effective medicines of evidence-based medicine in this area is quite limited. Vinpocetine (Cavinton) is one of the drugs that effectively selectively corrects cerebral perfusion. The use of alternative ways of absorption of vinpocetine (rectal and nasal) in certain soft application dosage forms will allow to significantly increase the bioavailability of the medicinal substance, reduce the level of adverse reactions from its use and expand the pharmacotherapeutic arsenal of domestic effective neuroprotective drugs. Taking into account the above, the employees of the Department of Medicines Technology of Zaporizhzhia State Medical University, on the basis of complex physical-chemical, pharmacotechnological, rheological and biopharmaceutical research, proposed rational formulations and technologies of two new soft application dosage forms of vinpocetine – rectal suppositories on a lipophilic basis and nasal cream on an emulsion basis for the therapy of arterial hypertension of II–III stages with cerebrovascular complications, reduction of the manifestation of neurological and/or mental symptoms in various forms of cerebral blood circulation insufficiency, consequences of a stroke, transient ischemic attack, etc.
The aim of the work is to study the specific activity of the proposed innovative application dosage forms of vinpocetine.
Materials and methods. Nasal ointment containing 0.5 % vinpocetine on an emulsion basis and rectal suppositories with vinpocetine 0.01 g on a lipophilic carrier were used as the object of preclinical studies, which ensure optimal release of the active pharmaceutical ingredient. The study of the specific activity of the developed medicinal forms of vinpocetine was carried out on a model of acute cerebrovascular accident of the type of ischemic stroke. Vinpocetin tablets (Astrapharm, Ukraine), which are used in neurological practice quite effectively and over a long period of time, were used as a comparison drug.
Results. The comparative results showed that the appointment of all studied drugs led to an increase in motor activity. In addition, the administration of medicinal forms of vinpocetine reduced the development of cognitive and cognitive disorders after acute disorders of cerebral blood circulation. It was found that the highest result was shown by the group of animals that received a course of vinpocetine intranasally. In the groups of animals that received vinpocetine for 4 days, markers of oxidative stress – aldehyde phenylhydrazones and ketone phenylhydrazones – were significantly reduced. The highest activity was demonstrated by the pharmaceutical form of vinpocetin, which was used intranasally for 4 days. The introduction of dosage forms of vinpocetine exerted an energizing effect, which was expressed in an increase in the level of macroergic phosphates. Evidently, vinpocetine has a direct positive effect on the three-carbon sections of the Krebs cycle and increases the production of adenosine triphosphate (ATP). At the same time, the vinpocetine nasal cream applied intranasally for 4 days demonstrated the greatest energizing activity.
Conclusions. Preclinical studies of the developed application soft medicines with vinpocetine on the model of acute cerebrovascular accident type ischemic stroke experimentally confirmed the expressed neuroprotective activity of rectal suppositories and nasal cream with vinpocetine and it was found that the effectiveness of therapy with these application medicinal forms is demonstrably higher than that in comparison with oral tablet means.
Hu, X., De Silva, T. M., Chen, J., & Faraci, F. M. (2017). Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke. Circulation research, 120(3), 449-471. https://doi.org/10.1161/CIRCRESAHA.116.308427
Lau, W. L., Huisa, B. N., & Fisher, M. (2017, February 1). The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms. Translational Stroke Research. Springer US. https://doi.org/10.1007/s12975-016-0499-x
Dubey, A., Kumar, N., Mishra, A., Singh, Y., & Tiwari, M. (2020). Review on Vinpocetine. International Journal of Pharmacy & Life Sciences, 11(5), 6590-6597. Retrieved from http://www.ijplsjournal.com/issues PDF files/Archive-2020/May-2020/2.pdf
Zhang, C., Hsu, C. G., Mohan, A., Shi, H., Li, D., & Yan, C. (2020). Vinpocetine protects against the development of experimental abdominal aortic aneurysms. Clinical science, 134(22), 2959-2976. https://doi.org/10.1042/CS20201057
Kechyn, I. L., Hladyshev, V. V., & Pukhalska, I. O. (2021). Porivnialna farmakodynamika kaptoprylu pry intranazalnomu y enteralnomu shliakhakh vvedennia pry neuskladnenykh hipertenzyvnykh kryzakh na ambulatornomu etapi likuvannia [Comparative pharmacodynamics of intranasal and enteral administration of captopril for uncomplicated hypertensive crises]. Current issues in pharmacy and medicine: science and practice, 14(1), 103-108. [in Ukrainian]. https://doi.org/10.14739/2409-2932.2021.1.226857
Nagornaya, N. A., Gladyshev, V. V., & Burlaka, B. S. (2014). Study of vinpocetine intranasal dosage form consistence properties. Zaporozhye Medical Journal, (5), 97-100. https://doi.org/10.14739/2310-1210.2014.5.29149
Nagornaya, N. A., Gladyshev, V. V., Nаgоrniy, V. V., & Burlaka, B. S. (2013). O vliyanii vida nositelya i poverkhnostno-aktivnykh veshchestv na vysvobozhdaemost' vinpotsetina iz suppozitoriev [About influence of the kind of the carrier and surfactants on release vinpocetin from suppositories]. Current issues in pharmacy and medicine: science and practice, (2), 30-32. [in Russian].
Chekman, I. S., Belenichev, I. F., Nagornaya, E. A., Gorchakova, N. A., Luk'yanchuk, V. D., Bukhtiyarova N. V., & Gorbachev S. V. (2016). Doklinicheskoe izuchenie spetsificheskoi aktivnosti potentsial'nykh lekarstvennykh sredstv pervichnoi i vtorichnoi neiroprotektsii [Preclinical study of the specific activity of potential drugs for primary and secondary neuroprotection: guidelines]. Kiev : OOO Izdatel'stvo "Yuston". [in Russian].
Belenichev, I. F., Chernii, V. I., Kolesnik, Yu. M., Pavlov, S. V., Andronova, I. A., Abramov, A. V., Ostrovaya, T. V., Bukhtiyarova, N. V., & Kucherenko, L. I. (2009). Ratsionalnaia neiroprotektsiia [Rational neuroprotection]. Dotetsk: Izdatel Zaslavskii A. Yu. [in Russian].
Stephanov, A. V. (2002). Doklinicheskie issledovaniia lekarstvennykh sredstv (metodicheskie rekomendatsii) [Preclinical studies of drugs (guidelines)]. Kiev: Avitsenna [in Russian].
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)